EUVIMEDEUVIMED entdecken
Fallbericht

Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy

Hong T Lin, Kathryn A Wikenheiser-Brokamp, Gavin Udstuen, Blaise Jones, Francis X McCormack

CHEST · 2023

DOI: 10.1016/j.chest.2022.10.003 ↗

Kurz gefasst

Fallbericht in der Zeitschrift CHEST, 2023. Verfasst von Hong T Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: linht@mail.uc.edu. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Histiocytosis, Langerhans-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple trials have demonstrated the efficacy of therapies targeting the RAS/MAPK pathway in children with Langerhans cell histiocytosis (LCH), but less is known about the success of this strategy in adults or in LCH that is the result of mutations other than BRAF V600E. A 53-year-old woman who has never smoked presented to our clinic with multisystem, multifocal LCH that resulted from an uncommon BRAF N486_P490del mutation. Low dose, and even intermittent, MEK inhibitor (trametinib) therapy was associated with rapid improvement in almost all of her disease manifestations, including regression of masses in her groin and neck, reduction in seizure frequency and intensity, improvement in white matter lesions on MRI, diabetes insipidus, dyspnea, and cognitive and memory functions. We conclude that MEK inhibitor therapy was effective for BRAF mutation-associated adult multisystem LCH, including CNS manifestations, in this patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafHistiocytosis, Langerhans-CellHumansAdultChildFemaleMiddle AgedProtein Kinase InhibitorsNeckMutationMitogen-Activated Protein Kinase Kinases

Stichwörter der Autor:innen

BRAFLangerhans cell histiocytosisMekinistN486_P490deltrametinib

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: linht@mail.uc.edu.
  • Division of Pathology & Laboratory Medicine and Perinatal Institute Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pathology & Laboratory Medicine, University…
  • Gardner Neuroscience Institute, Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH.
  • Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH.
  • Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.

Zitieren

APA

Lin, H. T., Wikenheiser-Brokamp, K. A., Udstuen, G., Jones, B., & McCormack, F. X. (2023). Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy. CHEST. https://doi.org/10.1016/j.chest.2022.10.003

Vancouver

Lin HT, Wikenheiser-Brokamp KA, Udstuen G, Jones B, McCormack FX. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy. CHEST. 2023. doi:10.1016/j.chest.2022.10.003

BibTeX
@article{Lin2023,
  author = {Lin, Hong T and Wikenheiser-Brokamp, Kathryn A and Udstuen, Gavin and Jones, Blaise and McCormack, Francis X},
  title = {Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy},
  journal = {CHEST},
  year = {2023},
  doi = {10.1016/j.chest.2022.10.003}
}
Kostenlos starten →